clinical trial · NCT07309900
IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology·phase1·recruiting·n = 12
Relapsed/Refractory B-cell MalignanciesIASO208 injection
brief summary
This is an investigator-initiated, single-arm, open-label clinical study. It employs a dose-escalation design to evaluate the safety, pharmacokinetics, and preliminary efficacy of IASO208 injection in relapsed/refractory B-cell malignancies.
started
Nov 21, 2025
primary completion
Dec 15, 2028
completion
Jun 15, 2029
last updated
Jan 12, 2026
official title
A Single-arm, Open-label Exploratory Clinical Study of IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol